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Abstract 
Aims: Lamin A/C mutations are generally believed to be associated with a severe prognosis. It 
was the aim to investigate the disease expression in three affected families carrying different 
LMNA missense mutations. Furthermore, the potential molecular disease mechanisms of the 
mutations were investigated in fibroblasts obtained from mutation carriers. 
Methods and Results: A LMNA-p.Arg216Cys missense mutation was identified in a large 
family with 36 mutation carriers. The disease expression was unusual with a late onset and a 
favourable prognosis. Two smaller families with a severe disease expression were shown to carry 
a LMNA-p.Arg471Cys and LMNA-p.Arg471His mutation, respectively. LMNA gene and protein 
expression was investigated in eight different mutation carriers by Western blotting, 
immunohistochemistry, quantitative reverse transcriptase PCR, and protein mass spectrometry. 
The results showed that all mutation carriers incorporated mutated lamin protein into the nuclear 
envelope. Interestingly, the ratio of mutated- to wild type- protein was only 30:70 in LMNA-
p.Arg216Cys carriers with a favourable prognosis while LMNA-p.Arg471Cys and LMNA-
p.Arg471His carriers with a more severe outcome expressed significantly more of the mutated 
protein by a ratio of 50:50.  
Conclusion: The clinical findings indicated that some LMNA mutations may be associated with 
a favourable prognosis and a low risk of sudden death. Protein expression studies suggested that 
a severe outcome was associated with the expression of high amounts of mutated protein. These 
findings may prove to be helpful in counselling and risk assessment of LMNA families.  
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Introduction 
Mutations in the gene for lamin A and lamin C (LMNA) are associated with the 
development of cardiac conduction disease (CCD), atrial and ventricular arrhythmias, muscular 
dystrophy, and dilated cardiomyopathy (DCM).1, 2 Recently, a European multicentre study of 269 
LMNA-mutation carriers suggested that the presence of two or more risk-factors including an 
episode of non-sustained ventricular tachycardia (VT), a left ventricular ejection fraction (LVEF) 
< 45%, male sex, and non-missense mutations were associated with a high risk of malignant 
ventricular arrhythmias (VA) and sudden cardiac death (SCD). 3, 4 These observations were 
recently confirmed in a study of 122 LMNA-mutation carriers in the US.5 However, novel data 
suggest that some LMNA mutations may be associated with a more benign outcome.6 
Lamin A and lamin C proteins constitute the main structural proteins of the inner nuclear 
envelope. Both isoforms are transcribed from the LMNA gene through alternative splicing of 
messenger RNA (mRNA).7 They are expressed in almost all differentiated tissues including the 
myocardium and fibroblasts. In addition to their structural and supportive function of the 
nucleus, these proteins are believed to influence regulation of gene expression through an 
interaction with transcription factors, DNA, and chromatin.7 It has been suggested that 
haploinsuffiency is the disease mechanism in patients carrying truncating LMNA mutations, 
while LMNA missense mutations have been proposed to act through a dominant negative 
pathway.8-10 A recent study of a missense mutation suggested that mutant lamin protein may 
accumulate and form intra-nuclear aggregates and thereby exhibit a dominant negative effect.11 
In the current study, we report the disease expression associated with a LMNA-p.Arg216Cys 
variant in a large family with 36 mutation carriers. The phenotype was remarkable since most of 
Slettet: -
Slettet: -
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the affected mutation carriers had a late onset of disease manifestations and a favourable 
prognosis. Furthermore, we describe two additional LMNA families with a total of 17 mutation 
carriers, which were characterised by an early onset and a severe disease expression of DCM. To 
elucidate if the highly variable disease expression observed in the three families was associated 
with different molecular disease mechanisms we performed gene and protein expression studies 
in fibroblasts obtained from LMNA mutation carriers.   
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Methods 
Subjects and clinical investigations 
The study included three unrelated index patients who carried a disease associated LMNA 
mutation and their relatives who accepted an offer of clinical investigation including 12-lead 
ECG-recording, two-dimensional Doppler echocardiography, and 48-hour Holter-monitoring. 
DCM in index-patients was defined as LV end-diastolic volumes or -diameters >2 standard 
deviations (SD) from normal and LVEF < 0.45.12 VA were defined as sustained VT lasting >30 
s, non-sustained VT as >3 ventricular ectopics with a frequency of > 120 beats/minute, or as 
ventricular fibrillation. Relatives were diagnosed in accordance with recent recommendations.13 
Coronary artery disease was excluded by coronary angiography in patients older than 40 years. 
The study was carried out in accordance with the Declaration of Helsinki. The local ethics 
committee approved the study and informed consent was obtained from all participants (protocol 
no. VEK S-20140073). 
 
Genetic diagnosis 
Index-patients underwent genetic testing in 84 cardiac specific genes as previously 
reported and relatives at risk were offered predictive testing for the specific variant identified in 
the index patient.14 Genetic investigations of deceased individuals were made with DNA 
extracted from formalin-fixed paraffin embedded tissue.  
Cell cultures 
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Fibroblast cell lines were established from skin biopsies of eight individuals with LMNA 
mutations and three healthy controls as previously described.9 
 
Quantitative reverse transcriptase PCR (qRT-PCR)  
cDNA was synthesized from RNA extracted from cultured fibroblasts as previously 
described.9 For qRT-PCR analysis, custom designed Taqman gene expression assays covering 
both LMNA(Hs00153462_m1) and TUBA4A (Hs01081795_g1) transcripts were used. Step One 
Plus (Life technologies) was used to analyse the samples as triple determinations. LMNA gene 
expression levels were normalised to α-tubulin levels.  
 
Western blotting (WB)  
The cytoskeletal protein fractions were extracted from patient and control fibroblasts 
visualised by WB as previously described.9 Primary antibodies used were: anti-lamin A/C (N-
terminal epitope, Sigma-Aldrich, #HPA006660) and anti-α-tubulin (Sigma-Aldrich, #T6074), 
followed by incubation with secondary antibodies (goat-anti-mouse- or goat-anti-rabbit-HRP, 
DAKO) in one hour. ECL-Plus (Thermo Scientific) was used for protein detection. ImageQuant 
LAS 4000 (GE Healthcare) was used for visualisation.  
 
Targeted mass spectrometry analysis of lamin proteins  
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Targeted mass spectrometry analysis of lamin proteins was performed as previously 
described.15 Twenty-five µg of the extracted proteins from the isolated cytoskeletal fraction from 
each sample was separated by SDS-PAGE. The gel pieces containing the proteins of interest, 
lamin A and lamin C, migrating between 100 and 40 kDa in-gel were digested by trypsin. A mix 
of heavy labelled peptides covering the mutation sites and other parts of lamin A and lamin C 
(Supplementary Table S2) was added to each peptide sample, followed by selected reaction 
monitoring (SRM) using nano-liquid chromatography coupled with tandem mass spectrometry 
(TSQ Vantage, Thermo Scientific, see Supplement S2 for details).15 Skyline software was used 
to assure correct peptide identifications and to calculate the ratios between the light 
(endogenous) and the heavy (internal standard) peptides.16 The peptide mass data were validated 
according to retention time and fragmentation pattern. For quantitation, the ratio of the area 
under the curve of endogenous peptide to heavy labelled peptide was calculated.  
 
Histology and Immunohistochemistry of cardiac tissue and fibroblasts  
Myocardial tissue was available from one carrier for each LMNA mutation. Samples from 
non-LMNA DCM patients served as controls (n=4). Four µm thick formalin-fixed paraffin-
embedded sections of myocardial tissue were plated on glass coverslips and were stained with 
either hematoxylin and eosin, or with mouse anti-lamin A/C antibody (#4C11, Cell Signalling 
technology) followed by incubation with anti-IgG mouse Alexa-Fluor-488-conjugated antibody 
(Invitrogen). The slides were imaged using a confocal laser scanning microscope (Leica TCS 
SP8). Immunocytochemistry staining of cultured fibroblasts was performed with similar 
antibodies as previously described.9 
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Statistics 
Normally distributed data are expressed as means ± SD or otherwise as medians with 
interquartile ranges. Statistical analyses were performed using Student’s t-test with significance 
level of 0.05. 
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Results 
Clinical investigations and genetic diagnosis 
For a complete overview of clinical features in mutation carriers, see Table S1 in the Data 
Supplement.  
 
Family A 
The proband of family A, (IV-9), presented at the age of 59 with sustained VT (Fig. 2A, 
Table S1). Following cardioversion ECG monitoring showed sinus node dysfunction and 
advanced second degree AVB. Echocardiography showed a dilated LV with a LVEF of 40%. An 
ICD was implanted and he has subsequently received appropriate ICD-therapy multiple times 
due to sustained VT. Genetic investigations identified a novel LMNA-p.Arg216Cys/c.464C>T 
variant which was considered to be disease associated since it segregated with the condition in 
the family and was absent in more than 60.000 ExAC exomes.17  
Clinical cascade screening identified 12 affected individuals (mean age 68 years, range: 
59-87) who all carried the mutation (Fig. 1+2A and Table 1+S1). All had CCD with advanced 
AVB of which six had been diagnosed before this investigation. Family investigations identified 
five patients with total AVB of which one, (III-8), declined the offer of pacemaker implantation 
two years before he died at the age of 89 years. All but one, (IV-6), had chronic or paroxysmal 
SVA while eight fulfilled diagnostic criteria of familial DCM with an average LVEF of 40%. 
Only one relative, (IV-4), received appropriate ICD-therapy during follow-up, while another, 
(IV-27), received a cardiac transplant at the age of 50 due to end-stage heart failure. This patient 
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however had extensive cardiac sarcoidosis confirmed by histological examination of the 
explanted heart, which was believed to be the main cause of her condition.  
A total of 17 healthy mutation carriers (mean age 49 years, range: 23-68, Table S1) were 
identified. Five of these individuals developed advanced AVB with preserved LV function and 
no significant VA during an average follow-up period of 5.2 years at a mean age of 60 years 
(range: 55-69). One younger mutation carrier, (V-9), had 10% monomorphic premature 
ventricular contractions (PVCs) originating from the right ventricular outflow tract and short 
episodes of non-sustained VT of similar morphology on Holter monitoring. She had mild LV 
dysfunction (LVEF 0.50) without structural abnormalities or late gadolinium enhancement on 
cardiac magnetic resonance imaging. The patient underwent successful ablation for the 
arrhythmic substrate and no VA have been detected during five years of follow-up. In addition, 
her LV function normalised without medication. It is unclear if the disease expression of this 
patient was related to the genotype or if she represented a phenocopy with a different cause of 
her PVCs. 
A total of six deceased obligate mutation carriers were identified with little clinical 
information available, (Fig. 2A, Table S1). One of these individuals (II-2) died of cancer at the 
age of 54, while the remaining individuals died at an average age of 77 years, which indicated a 
near normal life expectancy despite their genotype. 
In summary, during this investigation 20 of 36 (46%) mutation carriers were affected or 
developed disease manifestations that required device implantation at an average age of 61.7 
years. Although all affected individuals had or developed advanced AVB requiring pacemaker 
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implantation only two patients (5%) including the proband had significant VA. Only nine of 36 
(25%) mutation carriers fulfilled diagnostic criteria of DCM. 
 
Family B 
The proband, (III-3), was diagnosed with DCM (LVEF 0.35) at the age of 54 and has 
remained stable on heart failure therapy for the past 6 years (Fig. 1+2B, Table 1+S1). Her son, 
(IV-6), died suddenly at the age of 18 while at rest and autopsy revealed an enlarged heart 
consistent with a diagnosis of DCM. The brother, (IV-5), of the deceased was diagnosed with 
DCM (LVEF 0.40) at the age of 25 and was treated with a prophylactic ICD from which he has 
received appropriate anti-tachycardia pacing once during twelve years of follow-up. Family 
investigations identified three additional surviving relatives with DCM of which one received a 
cardiac transplant at the age of 59, (III-5). Four mutation carriers had died prior to this 
investigation from CHF at an average age of 61 years.  
Genetic investigations identified a novel LMNA-p.Arg471His/c.1412G>A mutation. The 
mutation co-segregated with the disease in the family. Genetic cascade screening identified three 
healthy gene carriers with an average age of 38 years (one individual lost to follow-up). The 
p.Arg471His mutation was considered pathogenic since it co-segregated with the DCM-
phenotype in this family, was absent in the ExAC control exomes17, and has been reported 
previously in a DCM-patient.18 
 
Family C 
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The proband was diagnosed at the age of 41 with atrial fibrillation (Fig. 1+2C, Table 
1+S1). He later developed DCM with a LVEF of 45% and received a dual-chamber pacemaker at 
the age of 45 years due to total AVB. Four years later he died suddenly at rest. Post-mortem 
examination of the heart was consistent with DCM. His sister developed DCM with an LVEF of 
25% at the age of 38 years and has had episodes of nsVT and sVT. 
Genetic investigations identified a LMNA-p.Arg471Cys/ c.1411C>T missense mutation 
carried by both affected individuals. The same mutation has been identified in three additional 
unrelated probands with DCM at our institution (unpublished data). The p.Arg471Cys variant 
was considered to be a likely pathogenic variant since it was located in the same codon as the 
recognised disease causing mutation identified in family B, (p.Arg471His), and the frequency 
among ExAC control alleles was very low (3/117.104).17 
In summary, the disease expression in family B and C appeared to be severe since 65% of 
mutation carriers had DCM of which seven (47%) had died from either CHF or SCD. 
Surprisingly, no one had CCD. The average age of onset of disease was 48 years (Table 1). 
 
LMNA gene and lamin A and C protein expression in mutant fibroblast cell lines 
LMNA transcript and protein levels in fibroblast of mutation carriers were measured by 
qRT-PCR and WB and were not significantly different from control fibroblasts (Fig. 3A+B). 
However, the specific expression of lamin C protein was significantly increased in mutation 
carriers (Fig. 3C). This finding was supported by SRM MS analysis which showed that the 
expression of a lamin A-specific peptide relative to expression of common lamin A and lamin C 
peptides from p.Arg471His and p.Arg216Cys fibroblasts was lower compared to peptides from 
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control fibroblasts (Fig. 3D). In accordance with the result by WB this finding indicated that 
expression of the lamin C isoform was relatively increased compared to lamin A expression in 
mutation carriers.  
  
Lamin A and C proteins in the cytoskeletal fraction of cells 
Mutant lamin A/C peptides were identified and discriminated from wild type (WT) 
peptides by use of heavy-isotope labelled mutant peptides in the SRM MS analysis. In 
p.Arg216Cys fibroblasts SRM analysis was able to detect the endogenous mutant peptide 
NIYSEELCETK (red in fig. 4A, variation in bold) with high intensities (Fig. 4A). Similarly, the 
mutant peptides HQNGDDPLLTYR and CQNGDDPLLTYR were detectable in p.Arg471His 
and p.Arg471Cys fibroblast cells, respectively (Fig. 4B+C). As expected, the mutant peptides 
were not present in controls. 
Quantification of the WT peptide corresponding to the mutated p.Arg216Cys peptide 
demonstrated that the WT peptide accounted for approximately 70% of total lamin A and C 
protein in p.Arg216Cys fibroblasts (Fig. 4D). In contrast, only 50 % of the lamin protein was 
derived from the WT allele in the LMNA-p.Arg471His- and LMNA-p.Arg471Cys carriers 
indicating that these mutant lamin proteins were incorporated in the cytoskeletal fraction with 
similar efficiency as the WT protein (Fig. 4D).  
 
Immunohistology   
Histological examination did not show any obvious differences between LMNA and non-
LMNA DCM patients (Suppl. Figure S1). Antibody staining with an anti-LMNA antibody 
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demonstrated nuclear staining in all LMNA-patients without cytosolic aggregates which indicated 
nuclear incorporation of mutant lamin protein. Additional immuno-staining of p.Arg471His 
fibroblasts showed a normal nuclear morphology without intracellular aggregates supporting the 
expression and incorporation of mutated protein into the cytoskeleton (Sup. Figure S2).
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Discussion 
Clinical and genetic investigations 
Several clinical investigations have shown that LMNA-mutations in cardiac conditions are 
associated with a severe prognosis and that the presence of specific risk factors are associated 
with an increased risk of VA and sudden death.3-5 The disease expression in family B and C was 
in accordance with previous findings and showed that more than half of the patients died from 
CHF or VA. In contrast, the clinical investigations in family A, which included 36 carriers of the 
p.Arg261Cys mutation, showed a late onset of disease manifestations and a low frequency of 
VA. A substantial part of the mutation carriers had a near normal life span of which one patient 
even survived until the age of 89 years without a pacemaker, despite the presence of a complete 
AVB. Overall, the disease expression was associated with an apparently mild phenotype and few 
adverse disease complications which suggested that LMNA mutations may also be associated 
with a favourable prognosis. These findings were consistent with the results of recent Dutch 
study of a LMNA-p.Arg331Gln mutation in 57 mutation carriers, which was also associated with 
a lower risk of VA, end-stage CHF and SCD than previously anticipated.6  
So far clinical and genetic data of LMNA families have largely been provided by 
investigations of highly selected families at tertiary referral centres, which may introduce 
selection bias towards severely affected families.1, 2, 4, 5, 19, 20 The results of the current study 
underscore the importance of investigating the entire family and assess the phenotype of all 
individuals at risk of having inherited the condition to provide a firm basis for individualised risk 
assessment. 
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Expression studies  
For the first time to our knowledge protein MS was used to perform targeted analyses of 
wild type and mutant lamin A and C protein expression in heterozygous mutation carriers. The 
results showed that the mutated peptides were present in the cytoskeletal protein fraction and 
thereby likely to be incorporated into the nuclear lamin polymer. Furthermore, SRM revealed 
that the ratio of WT and mutated protein was 50:50 in fibroblasts obtained from mutation carriers 
of p.Arg471His and p.Arg471Cys in whom the disease expression was associated with a severe 
outcome. Interestingly, the proportion of mutant protein was only 30% in mutation carriers of 
p.Arg216Cys which may explain the apparently milder disease expression, although further 
conformational studies of additional families need to be performed. However, the results of the 
current study indicated that the proportion of incorporated mutant lamin protein may serve as a 
prognostic marker of disease which has the potential to improve current algorithms for risk 
assessment of individual LMNA families. 
The mutations investigated were all located in the common region of lamin A/C and 
thereby expected to affect both isoforms equally. However, the experimental results indicated 
that the protein expression levels of lamin A were unaffected in mutant cells. Surprisingly, the 
expression of lamin C protein was significantly increased in mutation carriers, leading to a 
decreased lamin A to lamin C ratio in LMNA carriers. This finding was also observed in our 
previous study of fibroblasts from carriers of a truncating LMNA-p.Arg321X mutation.9 
Similarly a decreased lamin A to lamin C ratio at mRNA and protein level has been observed in 
patients with progeria and Emery-Dreifuss muscular dystrophy.21, 22 The impact of these findings 
remain unclear and needs to be investigated further. 
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Immunohistochemistry of cardiac tissues and p.Arg471His fibroblasts did not show 
intracellular aggregates of mutant lamin protein (Sup. Fig. 1 and 2). Therefore, it is likely that the 
combination of a skewed lamin A to C ratio and the incorporation of mutated protein may lead to 
destabilisation of the nuclear envelope and impair the mechanical support of the nucleus. The 
results support the hypothesis that LMNA missense mutations act by a dominant-negative disease 
mechanism.18, 23-25 
 
Limitations  
Skin fibroblasts are easily accessible from mutation carriers compared to cardiac tissue. In 
addition, these fibroblasts are likely to share the same genetic background as cardiomyocytes of 
the patients, which may minimise potential bias compared to in vitro studies of mutations 
expressed in artificial cell systems unrelated to the patient. However, studies on protein functions 
in fibroblasts need confirmation in cardiac tissue in which the electromechanical coupling is a 
complex interplay between myocytes, fibroblasts, and extracellular matrix. 
 
Conclusion 
The clinical investigations of a large family with a novel pathogenic LMNA mutation 
showed that the disease expression of LMNA mutations may also be associated with a favourable 
prognosis in contrast to the findings in most previous reports. Furthermore, the results suggested 
that the clinical outcome in LMNA mutation carriers may be associated with the amount of 
mutant peptide incorporated into the nuclear envelope.  
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Figure legends 
Figure 1: Clinical endpoints according to age in LMNA mutation carriers. Abbreviations; HTX, 
heart transplantation; SUD, sudden unexpected death; ICD, implantable cardioverter 
defibrillator; PM, pacemaker; VT, ventricular tachycardia; SVA, supraventricular arrhythmias; 
DCM, dilated cardiomyopathy; AVB/LBBB, atrioventricular block or left bundle branch block.  
 
Figure 2: Pedigrees of LMNA-families. Square, male; circle, female; filled symbols, affected; 
grey symbols, possibly affected; crossed symbols, deceased; +, mutation carrier; -, non-mutation 
carrier; ?, unknown genetic status. 
 
Figure 3: (A) qRT-PCR analysis of LMNA transcript levels relative to α–tubulin (TUBA4A) in 
healthy controls and in LMNA-p.Arg471His and LMNA-p.Arg216Cys fibroblasts. Error bars 
denote standard deviation. (B) Western blot analysis. Representative Western blot detecting 
lamin A and lamin C proteins from the cytoskeletal fraction of patient and control fibroblasts. α-
tubulin was used as a loading control. (C) Quantitation of band intensities, from Figure 3A, of 
lamin A and lamin C relative to α-tubulin. Columns represent the means of signal intensities of 
lamin A and lamin C relative to α-tubulin. Error bars denote standard deviation; *p <0.05. (D) 
Lamin A and lamin C ratio quantitation by SRM. Schematic overview of lamin A and lamin C 
(lamin A/C) common peptides 1-3 (black) and lamin A specific peptide 4 (grey) used for the 
quantitation of lamin A to lamin C ratio. The graphs represent relative quantitation of lamin A to 
lamin A/C peptides by SRM-nLC-MS/MS in control and patient fibroblasts. The quantitative 
robustness was improved by utilization of isotopically labelled peptide standards, for each 
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quantified peptide, and by normalisation to the reference protein α-tubulin (Supplement S1). 
Error bars denote standard deviation.   
 
Figure 4: SRM mass spectrometry detection of variation specific peptides of lamin A and lamin 
C in the cytoskeletal fraction of patient fibroblasts. Endogenous peptide signal depicted in red.  
The corresponding heavy labelled standard peptides (blue) were detectable in both control and 
patient samples (A) Representative chromatogram of the mutant peptide (red), NIYSEELCETK. 
The peptide was only detected in the p.Arg216Cys patient. (B) Representative chromatogram of 
the endogenous mutant peptide, HQNGDDPLLTYR detected in patient carrying the 
p.Arg471His mutation and not in control. A small peak representing signal from noise, at a 
mismatched time point, was detected in control. (C) Chromatogram representing the endogenous 
mutant peptide (red), CQNGDDPLLTYR, detected in the patient with the p. Arg471Cys 
mutation. (D) Calculations of the relative amounts of wild type lamin A and lamin C in the 
cytoskeletal fractions of patient and control fibroblasts. The wild type peptides covering the 
respective mutation sites (WT) only present in lamin A and lamin C from the wild type allele and 
three reference peptides present in both wild type and mutant lamin A and C sequences (1, 2, and 
3) were detected, quantitated by SRM, and used for the calculations of the fractions of wildtype 
and mutant protein (for details see Supplement S1). Error bars denote standard deviations.  
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Table 1 
 LMNA-p.Arg216Cys (n=36) LMNA-p.Arg471His/Cys (n=17) 
Clinical event  n (%) Mean age 
(range) 
n (%)  Mean age (range) 
Unaffected at last follow up 11 (31) 50 (27-60) 4 (24) 32 (19-40) 
Conduction disease 17 (47) 66 (50-89) 4 (24) 49 (36-64) 
Dilated cardiomyopathy 12 (33) 63 (34-89) 11 (65) 48 (18-64) 
Supraventricular arrhythmia 14 (39) 68 (53-89) 3 (18) 54 (40-64) 
Ventricular tachycardia 7 (19) 58 (32-69) 3 (18) 40 (25-59) 
Sudden unexplained death 2 (6) 65 (61-69) 4 (24) 46 (18-70) 
Pacemaker 17 (47) 62 (34-89) 2 (12) 48 (40-56) 
Implantable cardioverter defibrillator 11 (31) 59 (34-73) 5 (29) 46 (26-59) 
Heart transplantation 1 (3) 58 1 (6) 59 
All-cause death 11 (33) 73 (54-91) 8 (47) 53 (18-70) 
Legend: Clinical events according to age in LMNA mutation carriers. Clinical data from index patients and three first-degree relatives have been 
included in a previous paper.4 
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Supplementary online material 
Supplementary Figure S1: Nuclear morphology of cardiac tissues of patients and control. 
Immunofluorescence microscopy analysis of control and patient cardiac tissue. The 
immunofluorescent image showing lamin A/C (green) and alfa- actinin2 (red) detected with 
mouse anti-lamin A/C antibody and α-actinin-2, respectively. Myocardial tissues were stained 
with hematoxylin eosin.  
 
Supplementary Figure S2: Immunofluorescence microscopy analysis of control and patient 
fibroblasts. The immunofluorescent image showing lamin A/C (green) and cell nuclei (blue) 
detected with mouse anti-lamin A/C antibody and DAPI, respectively. 
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Supplementary Table S1 
ID/ sex Presentation Age* CCD2 DCM3 SVA4 VA5 Device6 Comment 
Family A: LMNA-p.Arg216Cys 
II-2/M  -/54      Died of cancer 
II-5/F  -/84      Unknown cause of death 
III-1/F  -/60      Unknown cause of death 
III-3/F CHF 89/91 AVB+LBBB(89) 57/45%(89) AFLU(89)  VVI-PM(89) Death cause unknown 
III-4/F  -/83      Died of cancer 
III-6/F  -/69      Sudden death 
III-7/F Syncope 62/74 AVB+LBBB(62)  AFIB(73)  VVI-PM(62) Stroke(74) 
III-8/M CHF 87/89 AVB+LBBB(87) 65/50%(87) AFLU(87)   CHF(89), declined PM 
III-11/F  -/54      Died of multiple sclerosis 
IV-1/M Bradycardia 59/75 AVB(59) 54/45%(67) AFIB(59) nsVT(69) DDD-PM(59) Died of cancer, IHD 
IV-3/M Postoperative 
AVB 
67/70 AVB(67) 60/40%(67) AFIB(67) 20% PVCs, 
nsVT(67) 
DDD-PM(67), 
CRT-D(67) 
Mitral valve surgery 
RFA-PVCs twice 
IV-4/M Svt 61/65 AVB(61) 50/49%(61) AFIB(61) 13% PVCs, 
sVT(61) 
DDD-ICD(61) RFA-VT trice. CMR with septal 
and RV LGE 
IV-6/F FS 73/78 AVB(73)    DDD-ICD(73)  
IV-9/M sVT 59/65 AVB(59) 57/40%(59)  11%PVCs, 
multiple 
sVT(65) 
DDD-ICD(59), 
CRT-D(65) 
RFA-VT twice 
IV-10/F FS 57/64 PRP(57), 
AVB+LBBB(59) 
 AFIB(61)  DDD-ICD(59) Mild limb-girdle  muscular 
dystrophy 
IV-12/F FS 73/76 PRP+AVB(73)  AFLU(73)  DDD-PM(73) RFA-AFLU(73) 
IV-14/F FS 70/75 AVB(70)  AFIB(70)  DDD-PM(70)  
IV-15/M FS 69/73 AVB(69)  AFLU(69)  DDD-ICD(69) RFA-AFLU(69) 
IV-16/M AVB 61/72 AVB(61) 
LBBB(69) 
73/10%(65) 
51/50%(70) 
AFLU(65) 
AFIB(66) 
 DDD-PM(61) 
CRT-D(65) 
IHD, PCI, RFA-AFLA(65) 
IV-24/F CHF 59/66 LBBB(59) 
AVB(64) 
68/30%(59) AFIB(59)  DDD-PM(59) 
CRT-P(62) 
Alcohol abuse, IHD, died of 
CHF 
IV-27/F CHF 50/58 AVB(50) 
LBBB(56) 
72/20%(56) AFIB(53) nsVT(56) DDD-PM(50) 
CRT-P(56) 
Cardiac sarcoidosis, HTX(58), 
Died of graft failure 
IV-29/M FS 59/64 SND+PRP(59) 
AVB(60) 
59/60%(62) AFIB(61)  DDD-ICD(60)  
IV-30/M FS 58/60    PVCs(60)   
IV-32/M FS 55/57       
IV-33/F FS 56/58       
IV-37/F FS 54/60 SND+PRP(54)   PVCs(55) DDD-ICD(57)  
28 
 
AVB(57) nsVT(57) 
IV-38/F FS 50/55 SND+PRP(50)   PVCs(55)   
V-9/F FS 31/38  59/50%(34) 
49/60%(38) 
 PVCs(32) 
nsVT(32) 
DDD-ICD(34) RFA-PVCs from RVOT(34). No 
VT on FU 
V-12/F FS 23/27       
V-16/M FS 50/54      Stroke(53) 
V-17/F FS 49/49       
V-18/F FS 48/48       
V-25/M FS 48/51  56/45%(50)   VVI-ICD(50) Normalisation of LVEF on FU 
V-27/F FS 43/47       
V-29/F FS 46/50       
V-30/M FS 41/45       
Mean age at endpoint (range) 64.4 (50-89) 63.0/(34-89) 67.6(53-89) 57.8(32-69) 61.7(34-89)  
 
Family B: LMNA-p.Arg471His 
I-1/M SUD 46      No autopsy, no gene test 
II-1/F CHF 57      No clinical data 
II-2/F CHF 57      No clinical data 
II-3/F CHF 60      No clinical data 
III-3/F FS 54/61 PRP(61) 57/40%(54)   VVI-ICD(54) Stroke 
III-5/M CHF 53/67 LBBB(59) 78/20%(59) AFIB(58) PVCs(56) CRT-D(56) HTX(59) 
III-6/M CHF 64/70 LBBB(64) 68/35%(64) AFIB(64) PVCs(68) Declined ICD SUD(70) 
III-7/F FS 59/59  54/50%(59)  nsVT(59) VVI-ICD(59) Lost to FU (foreign citizen) 
IV-5/M FS 25/37 LBBB(36) 57/35%(25)  PVCs(25) 
nsVT(25) 
VVI-ICD(26) Stroke 
IV-6/M SCD 18      Autopsy: DCM 
IV-10/M FS 22/36       
IV-11/M FS 34/40       
IV-13/M FS 32      Lost to FU (foreign citizen) 
Family C: LMNA-p.Arg471Cys 
I-1/M  -/55      Died from lung cancer, no gene 
test 
II-1/M Stroke/AFIB/br
adycardia 
40/49 AVB(40) 63/45%(40) AFIB(40) 
AFLU(42) 
 DDD-PM(40) Stroke(40), SCD(49), autopsy: 
DCM 
II-2/F FS 36/45 SND(45) 64/25%(41)  PVCs(36) 
nsVT(36) 
sVT (46) 
VVI-ICD(37) Stroke(35) 
III-3/F FS 15/19       
Table legend: Clinical characteristics of LMNA mutation carriers. Data from index patients and three first-degree relatives have been included in a 
previous paper.4 Value numbers in parenthesis indicate age. 1Age at initial evaluation and at death, HTx, or last follow-up; 2Cardiac conduction 
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disease including sinusnode dysfunction (SND), PR-interval prolongation (PRP; PR-interval >200 ms), atrioventricular block (AVB; advanced 
AVB type 2 or 3rd degree AVB), left bundle branch block (LBBB); 3Dilated cardiomyopathy defined as left ventricular dysfunction with ejection 
fraction < 0.50, or left ventricular end-diastolic dimensions >112% of the predicted value by the Henry formula (16); 4Supraventricular 
arrhythmias including atrial fibrillation (AFIB) or atrial flutter (AFLU); 5Ventricular arrhythmias including premature ventricular contractions 
(PVCs; >1000/24h), ventricular tachycardia (>3 consecutive PVCs at a heart rate above 120/min); 6Dual-chamber pacemaker (DDD-PM), 
implantable cardioverter defibrillator (VVI-ICD/DDD-ICD), or biventricular pacemaker or ICD (CRT-P/CRT-D). Abbreviations: AFIB, atrial 
fibrillation; AFLU, atrial flutter; CHF, chronic heart failure; FU, follow up; FS, family screening; HTx, cardiac transplantation; DCM, dilated 
cardiomyopathy; F, female; LVEF, left ventricular ejection fraction; IHD, ischemic heart disease; M, male; RFA, radiofrequency ablation; SCD, 
sudden cardiac death; SUD, sudden unexpected death; sVT, sustained ventricular tachycardia. 
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Supplementary Table S2 
Peptide Sequence Precursor (m/z) values Transitions (m/z) values 
Endogenous: Lamin A/C 
common peptides 
 
Heavy: Lamin A/C common 
peptides 
LKDLEALLNSK 
IDSLSAQLSQLQK 
MQQQLDEYQELLDIK 
LKDLEALLNS[K+4] 
IDSLSAQLSQLQ[K+4] 
MQQQLDEYQELLDI[K+4] 
622.37 
715.90 
947.47 
626.37 
719.90 
951.47 
1002.55, 887.52, 774.44, 645.39, 565.82 
1002.56, 915.53, 844.49, 603.35, 516.31 
1378.71, 1265.63, 1150.60, 1021.56, 817.92 
1010.56, 895.53, 782.45, 653.41, 569.83 
1010.57, 923.54, 852.50, 611.36, 524.33 
1386.72, 1273.64, 1158.61, 1029.57, 821.92 
Endogenous: Lamin A specific 
peptide 
Heavy: Lamin A specific 
peptide 
SVGGSGGGSFGDNLVTR 
 
SVGGSGGGSFGDNLVT[R+5] 
783.88 
 
788.88 
1179.58, 921.48, 774.41, 602.36, 690.83 
 
1189.58, 931.49, 784.42, 612.37, 695.83 
Endogenous: Lamin A/C WT 
peptides 
 
Heavy: Lamin A/C WT 
peptides 
NIYSEELR 
QNGDDPLLTYR 
 
NIYSEEL[R+5] 
QNGDDPLLTY[R+5] 
512.26 
646.32 
 
517.26 
651.32 
796.38, 633.32, 546.29, 417.25, 288.20 
877.48, 762.45, 552.31, 439.23, 338.18 
 
806.39, 643.33, 556.30, 427.25, 298.21 
887.49, 772.46, 562.32, 449.24, 348.19 
Endogenous: Lamin A/C 
mutant peptides 
 
Heavy: Lamin A/C mutant 
peptides 
HQNGDDPLLTYR 
CQNGDDPLLTYR 
NIYSEELCETK 
 
HQNGDDPLLTY[R+5] 
CQNGDDPLLTY[R+5] 
NIYSEELCET[K+4] 
714.85 
726.33 
693.32 
 
719.85 
731.34 
697.32 
1291.63, 1163.57, 1049.53, 762.45 
1163.57, 1049.53, 992.50, 877.48, 762.45 
1271.58, 1158.50, 995.44, 908.40, 779.36 
 
1301.64, 1173.58, 1059.53, 772.46 
1173.58, 1059.53, 1002.51, 887.49, 772.46 
1279.60, 1166.51, 1003.45, 916.42, 787.37 
Endogenous reference peptides: 
tubulin beta-5 chain (TBB5) 
 
Heavy reference peptides:  
tubulin beta-5 chain (TBB5) 
ISVYYNEATGGK 
ALTVPELTQQVFDAK 
 
ISVYYNEATGG[K+4] 
ALTVPELTQQVFDA[K+4] 
651.32 
830.45 
 
655.33 
834.46 
1188.55, 1101.52, 1002.45, 839.39,676.33 
1275.66, 936.48, 480.25, 687.87, 638.33 
 
1196.57, 1109.54, 1010.47, 847.40, 684.34 
1283.67, 944.49, 488.26, 691.87, 642.34 
Table legend: Endogenous and heavy labelled peptides used in SRM analysis 
